INHIBITION OF HIV-1 AND HIV-2 WITH ANTISENSE OLIGONUCLEOTIDES AND RIBOZYMES

用反义寡核苷酸和核酶抑制 HIV-1 和 HIV-2

• 批准号: 3792576
• 负责人: I K HEWLETT
• 金额: --
• 依托单位: CENTER BIOLOGICS EVALUATION RESEARCH TRANSFUSION
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3792576
• 关键词: AIDS; antiAIDS agent; antisense nucleic acid; human immunodeficiency virus 1; human immunodeficiency virus 2; liposomes; polymerase chain reaction; ribozymes; tissue /cell culture; virus antigen; zidovudine

Phosphorothioate modified antisense oligonucleotides (ASOs) have been designed complementary to various regulatory and structural genes of HIV-1. These ASOs are being evaluated for their anti-HIV activity using H9 and U937 cells as target cells. Antiviral activity is being assessed by p24 antigen and PCR. Preliminary results suggest that ASOs from the tat and the LTR regions were most effective in inhibiting virus expression. These ASOs are being packaged into liposomes and administered either singly or in combination with other ASOs or with AZT to target cells and their antiviral activity evaluated. Similar experiments are being performed with HIV-2. Oligonucleotides that allow the formation of ribozyme complexes or that interact with b-ribbon motifs on DNA are also being evaluated for their antiviral activity against HIV-1 and HIV-2.

硫代磷酸酯修饰的反义寡核苷酸（ASO）已经被广泛应用。 设计互补的各种调控和结构基因， HIV-1这些ASO正在使用以下方法评估其抗HIV活性： H9和U937细胞作为靶细胞。 正在评估抗病毒活性 p24抗原和PCR。 初步结果表明， 达特和LTR区域在抑制病毒方面最有效 表情这些ASO被包装到脂质体中， 单独或与其他ASO或AZT联合给药 靶向细胞并评价其抗病毒活性。 类似 实验是用HIV-2进行的。 寡核苷酸允许 核酶复合物的形成或与b-带相互作用 DNA上的基序也在评估它们的抗病毒活性 抗HIV-1和HIV-2。